FDC
437.75
+2.05(+0.47%)
Market Cap₹7,093.60 Cr
PE Ratio26.46
IndustryHealthcare
Company Performance:
1D+0.47%
1M-6.84%
6M+1.70%
1Y-19.91%
5Y+24.86%
View Company Insightsright
More news about FDC
07Aug 25
FDC Reports Steady Q1 Performance with Marginal Revenue Growth
FDC Limited's Q1 financial results show a steady performance. The company maintained a consolidated net profit of ₹120.00 crore, identical to last year's Q1. Revenue slightly increased to ₹650.00 crore from ₹640.00 crore, marking a 1.56% year-over-year growth. However, EBITDA decreased to ₹140.00 crore from ₹146.00 crore, with the EBITDA margin compressing to 21.54% from 22.81% year-over-year.
28May 25
FDC Reports Mixed Q4 Results: Revenue Up, Profit Down
FDC Limited's Q4 financial results show a 6.49% year-over-year revenue increase to ₹4.92 billion. However, profitability declined with EBITDA falling 4.12% to ₹539.80 crore and net profit decreasing 16.48% to ₹386.70 crore. The EBITDA margin compressed to 10.97% from 12.19% in the previous year.
30Apr 25
FDC Limited Approves Rs 140 Crore Expansion of Liquid Oral Facility at Sinnar Plant
FDC Limited has approved a Rs 140 crore expansion plan for its liquid oral facility at the Sinnar plant. The project will add 77,000 KL per annum to production capacity, to be completed in 18-24 months. Funded through internal accruals, this expansion aims to meet high capacity utilization (70-80%) and growing market demand. The investment is expected to strengthen FDC's manufacturing infrastructure and market position in the pharmaceutical sector.
FDC
437.75
+2.05
(+0.47%)
1 Year Returns:-19.91%
Industry Peers
Sun Pharmaceutical
1,679.10
(+1.21%)
Divis Laboratories
6,621.50
(+0.32%)
Cipla
1,577.60
(+0.52%)
Torrent Pharmaceuticals
3,584.30
(+1.43%)
Dr Reddys Laboratories
1,255.90
(+1.27%)
Mankind Pharma
2,476.60
(+0.87%)
Zydus Life Science
987.65
(+0.31%)
Lupin
1,940.00
(-0.57%)
Alkem Laboratories
5,581.50
(+1.04%)
Aurobindo Pharma
1,101.00
(-0.48%)